Does Affinity Health Plan Cover NovoLog? What You Need to Know

What Is NovoLog and Why Does It Matter for Diabetes Management?

NovoLog is the brand name for insulin aspart, a rapid-acting insulin analog manufactured by Novo Nordisk. It was first approved by the FDA in June 2000 for the treatment of type 1 and type 2 diabetes in adults, and later for pediatric use [1]. Because it begins working within 10 to 20 minutes of subcutaneous injection and peaks at 1 to 3 hours, it is specifically designed to control postprandial (after-meal) blood glucose spikes.

How NovoLog Differs from Regular Human Insulin

Regular human insulin (U-100 Regular) must be injected 30 minutes before meals to match its slower onset. NovoLog can be injected immediately before eating, or in some clinical protocols, immediately after a meal for patients with unpredictable appetite. That flexibility matters in real-world adherence. A 2002 trial published in Diabetes Care (N=448) showed insulin aspart produced significantly lower postprandial glucose excursions compared with regular human insulin (mean 2-hour glucose difference of approximately 36 mg/dL, P<0.001), with a comparable overall hypoglycemia rate [2].

FDA Approval and Clinical Indication

The FDA label for NovoLog covers subcutaneous injection, continuous subcutaneous insulin infusion (insulin pump use), and intravenous infusion in clinical settings [1]. Patients using insulin pumps particularly depend on rapid-acting analogs like NovoLog, because older formulations can crystallize in pump tubing. The American Diabetes Association (ADA) Standards of Care in Diabetes 2024 state that "most people with type 1 diabetes should be treated with multiple daily injections of prandial and basal insulin, or continuous subcutaneous insulin infusion" [3], making access to rapid-acting insulin a medically necessary issue, not simply a preference.

How Affinity Health Plan Formularies Work

Affinity Health Plan is a New York-based Medicaid managed-care organization (MCO) and Qualified Health Plan (QHP) issuer. It serves members enrolled in Medicaid, Child Health Plus, the Essential Plan, and Qualified Health Plans through the New York State of Health marketplace. Each product line maintains its own formulary, updated annually each January.

Formulary Tiers and What They Mean

Most Affinity formularies organize drugs into tiers:

• Tier 1: Preferred generics, lowest cost-sharing
• Tier 2: Non-preferred generics and some preferred brands
• Tier 3: Non-preferred brands, higher cost-sharing
• Tier 4: Specialty drugs, highest cost-sharing or step-therapy requirements

NovoLog as a brand-name product has historically appeared in Tier 2 or Tier 3 on many Medicaid MCO formularies in New York. Where a biosimilar insulin aspart (such as Trurapi, approved by the FDA in 2021) is listed as a preferred alternative, the brand-name NovoLog may require step therapy or prior authorization [4].

Prior Authorization Requirements

Prior authorization (PA) for NovoLog on Affinity plans is most likely to be triggered when:

1. A biosimilar or interchangeable insulin aspart product is on formulary at a lower tier.
2. The prescriber is requesting a quantity above the standard dispensing limit (for example, more than 10 mL vials per 30-day supply).
3. The patient is transitioning from a different insulin regimen and documentation of medical necessity is incomplete.

New York State Medicaid policy requires plans to respond to PA requests within 3 business days for non-urgent requests and 72 hours for urgent clinical situations [5]. Your prescriber can initiate the PA by submitting clinical notes, a recent HbA1c, and documentation of why the brand-name product is medically necessary over the biosimilar alternative.

Medicaid vs. Essential Plan vs. QHP Coverage

Coverage rules differ by product:

• Medicaid: New York Medicaid covers insulin with no copay for most members. PA requirements still apply.
• Essential Plan: Designed for adults aged 19 to 64 who earn 200% or less of the federal poverty level. Insulin copays are typically $0 to $3 per prescription.
• QHP (Qualified Health Plans): Members may face higher cost-sharing depending on the metal tier (Bronze, Silver, Gold) selected. The federal $35/month insulin cap applies only to Medicare Part D under the Inflation Reduction Act, not to commercial QHP plans unless the insurer has voluntarily adopted the cap [6].

Is NovoLog Covered on Affinity's Current 2025 Formulary?

Formulary lists change each plan year. As of the most recent publicly available Affinity formulary documents, insulin aspart products appear on the Affinity formulary, though the preferred product designation may favor the biosimilar version over brand-name NovoLog.

How to Verify Your Coverage Today

The most reliable way to confirm current coverage is to take one of these three steps:

1. Use the Affinity online drug lookup tool at the Affinity Health Plan website. Enter "insulin aspart" or "NovoLog" and select your specific plan type.
2. Call Affinity member services at 1-800-835-2362. Have your member ID, the drug name, and the NDC number from the pharmacy ready.
3. Ask your pharmacy to run a real-time eligibility check. Most pharmacy dispensing systems can query the plan in real time and return a coverage determination with the exact cost-sharing amount before you pay.

Getting confirmation in writing (or noting the date, time, and representative's name during a phone call) protects you if a coverage dispute arises later.

What If Affinity Denies Coverage?

If Affinity denies a NovoLog claim, New York law provides several remedies. You can file an internal appeal within 60 days of the denial, request an expedited appeal if your health is at immediate risk, or request an external appeal through the New York State Department of Financial Services after the internal process is exhausted [5]. The ADA's Standards of Care 2024 notes that "insulin is a life-sustaining medication," and denials of medically necessary insulin should be challenged with clinical documentation from your endocrinologist or primary care provider [3].

Biosimilar Alternatives to NovoLog That Affinity May Prefer

The FDA has approved two biosimilar insulin aspart products that are therapeutically equivalent to NovoLog:

• Trurapi (insulin aspart-aami): Approved by the FDA in November 2021, manufactured by Sanofi [4]. Trurapi has the same amino acid sequence as NovoLog and the same pharmacokinetic profile.
• Myxredlin (insulin aspart): An insulin aspart product marketed by Hikma Pharmaceuticals primarily for intravenous use in hospital settings.

Clinical Equivalence of Biosimilar Insulin Aspart

The FDA requires biosimilar approval to demonstrate no clinically meaningful differences from the reference product in terms of safety, purity, and potency [4]. A 2017 study in Diabetes, Obesity and Metabolism (N=525) compared a biosimilar insulin aspart to NovoLog in patients with type 1 diabetes and found no significant difference in HbA1c reduction (-0.17% treatment difference, 95% CI -0.30 to -0.04) or rates of hypoglycemia [7]. Switching patients from NovoLog to an approved biosimilar is therefore clinically reasonable when cost or formulary access is the driving factor. Patients using insulin pumps should confirm with their device manufacturer that the biosimilar has been validated for pump use before switching.

Interchangeability Designation

An "interchangeable" biosimilar can be substituted by a pharmacist without contacting the prescriber, similar to generic drug substitution. As of early 2025, the FDA interchangeability designation status for insulin aspart biosimilars should be confirmed on the FDA's Purple Book database [4]. If the product your pharmacy offers is designated interchangeable, your pharmacist can legally substitute it for NovoLog, which is how many Affinity members end up receiving the biosimilar even when the prescription says NovoLog.

Cost-Saving Options If Coverage Is Denied or Cost-Sharing Is High

Even when coverage exists, out-of-pocket costs can be a barrier. Several options reduce or eliminate costs for NovoLog.

Novo Nordisk Patient Assistance Program

Novo Nordisk operates a Patient Assistance Program (PAP) that provides NovoLog at no cost to uninsured or underinsured patients meeting income eligibility criteria (generally household income at or below 400% of the federal poverty level). Applications are available through the Novo Nordisk website or by calling 1-800-727-6500. Processing typically takes 2 to 4 weeks.

NovoCare Savings Card

For commercially insured patients (not Medicaid-eligible), Novo Nordisk's NovoCare program offers savings cards that may reduce NovoLog cost to as low as $99 per month for up to 3 vials or 2 packs of FlexPen. This option does not apply to Medicaid or government-funded insurance programs.

ReliOn NovoLog at Walmart

In 2021, Walmart began selling ReliOn NovoLog (insulin aspart) over the counter at a retail price of $72.88 per vial or $85.88 per FlexPen box in most states, without a prescription [8]. This is the same molecule (insulin aspart manufactured by Novo Nordisk) sold under the ReliOn private label. For Affinity members who face PA delays or denial, this option provides immediate access while the coverage issue is resolved. Note that using the OTC product bypasses the insurance claim entirely, meaning the cost does not count toward any deductible.

State Insulin Cost Laws in New York

New York State enacted legislation limiting insulin copays for state-regulated commercial insurance plans. As of 2023, New York law caps insulin cost-sharing at $100 per 30-day supply for commercially insured patients [9]. Medicaid and Essential Plan members are generally subject to even lower or zero cost-sharing for insulin under existing Medicaid rules.

Understanding the Broader Insulin Access Field

Access to insulin in the United States has been a documented public health concern. A 2021 study published in JAMA Internal Medicine analyzed insulin affordability and found that approximately 14% of adults with insulin-dependent diabetes reported cost-related underuse of insulin in the prior 12 months [10]. Among patients with lower incomes, that proportion was substantially higher. The ADA has formally stated that "affordable access to insulin is a public health imperative" [3].

The Role of Medicaid Managed Care in Insulin Access

Medicaid MCOs like Affinity receive a capitated payment from the state to cover all medical costs for enrolled members. Because formulary management directly affects their drug spend, MCOs have an incentive to prefer lower-cost biosimilar or generic products. New York State's Medicaid Drug Utilization Review (DUR) program provides oversight to ensure formulary restrictions do not create inappropriate barriers to medically necessary medications [5].

Type 1 vs. Type 2 Coverage Considerations

For patients with type 1 diabetes, rapid-acting insulin is not optional. The absence of endogenous insulin production means that missing a mealtime dose can lead to diabetic ketoacidosis (DKA) within hours. Insurers are generally required to cover rapid-acting insulin for type 1 patients without imposing step therapy requiring trial of a less effective alternative. For type 2 patients, some plans may require documentation that oral agents and basal insulin were tried before approving rapid-acting prandial insulin, though this varies by plan.

A 2019 Cochrane systematic review of rapid-acting insulin analogs versus regular human insulin (23 trials, N=8,128) found that rapid-acting analogs produced a statistically significant reduction in postprandial glucose (weighted mean difference approximately -1.4 mmol/L) with similar overall glycemic control (HbA1c) and a modest reduction in severe nocturnal hypoglycemia [11]. This evidence supports the clinical necessity argument for rapid-acting analogs over regular human insulin in appropriate patients.

What Your Prescriber Should Include in a Prior Authorization Request

If Affinity requires a PA for NovoLog, the clinical documentation that most strongly supports approval includes:

• Diagnosis codes for type 1 diabetes (E10.X) or type 2 diabetes with insulin use (E11.649)
• Current HbA1c value and date of test
• Documentation of prior insulin regimen and reason for requesting NovoLog specifically (for example, pump compatibility, documented hypoglycemia with other agents, or patient-specific pharmacokinetic needs)
• Prescriber attestation that the brand-name product is medically necessary and the biosimilar alternative is not clinically appropriate for this patient

The FDA's guidance on interchangeable biologics notes that "healthcare providers and patients should be aware that an interchangeable product may be substituted" but that prescribers retain the ability to indicate "dispense as written" to prevent substitution when clinically justified [4].

FAQ